Januvia (Sitagliptin)

Sitagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises the levels of the incretin hormones GLP‑1 and GIP, which in turn increase insulin secretion and decrease glucagon release in a glucose‑dependent manner, leading to better glycaemic control.

The dose of sitagliptin is determined by the prescribing clinician based on individual patient factors such as renal function and concomitant therapy. A common starting regimen is 100 mg taken once daily, but the prescriber may adjust the amount according to clinical response and safety considerations.

Safety of sitagliptin in pregnancy has not been established and it is classified as a pregnancy category of unknown risk. It should be used only if the potential benefit justifies the potential risk to the fetus. Sitagliptin is excreted in breast milk, so breastfeeding is not recommended unless the benefits outweigh the risks.

To order Januvia, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with sulfonylureas, sitagliptin has a lower risk of causing hypoglycaemia and is weight‑neutral. Unlike metformin, which primarily reduces hepatic glucose production, sitagliptin enhances the incretin pathway, offering an alternative mechanism of action that can be combined with other agents for additive glucose‑lowering effects.

Store Januvia at ambient temperature below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and avoid storing them in bathrooms or near heat sources to maintain product stability.

Januvia is taken orally, usually once daily. It can be swallowed with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and not alter the timing without medical advice.

The most serious adverse events associated with sitagliptin include acute pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and rare cases of hepatic injury. If patients experience persistent abdominal pain, swelling of the face or throat, or signs of liver dysfunction, they should seek immediate medical attention.

Patients with a known hypersensitivity to sitagliptin or any of its tablet excipients should avoid the medication. Individuals with a history of pancreatitis, or those with severe renal impairment where dose adjustment is not feasible, are also contraindicated. Clinicians should evaluate each patient’s medical history before initiating therapy.